Guggenheim Capital’s Ariad Pharmaceuticals Inc ARIA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q1 | – | Sell |
-253,807
| Closed | -$3.16M | – | 2997 |
|
|
2016
Q4 | $3.16M | Sell |
253,807
-31,725
| -11% | -$382K | 0.01% | 1310 |
|
|
2016
Q3 | $3.91M | Sell |
285,532
-66,935
| -19% | -$672K | 0.01% | 1163 |
|
|
2016
Q2 | $2.6M | Sell |
352,467
-26,101
| -7% | -$196K | 0.01% | 1399 |
|
|
2016
Q1 | $2.42M | Sell |
378,568
-217,880
| -37% | -$1.22M | 0.01% | 1441 |
|
|
2015
Q4 | $3.73M | Sell |
596,448
-157,231
| -21% | -$1.03M | 0.01% | 1181 |
|
|
2015
Q3 | $4.4M | Sell |
753,679
-91,936
| -11% | -$708K | 0.01% | 1111 |
|
|
2015
Q2 | $6.99M | Buy |
845,615
+133,295
| +19% | +$1.18M | 0.02% | 997 |
|
|
2015
Q1 | $5.87M | Buy |
712,320
+140,877
| +25% | +$1.04M | 0.01% | 1090 |
|
|
2014
Q4 | $3.93M | Buy |
571,443
+12,051
| +2% | +$75.4K | 0.01% | 1255 |
|
|
2014
Q3 | $3.02M | Buy |
559,392
+41,822
| +8% | +$244K | 0.01% | 1480 |
|
|
2014
Q2 | $3.3M | Sell |
517,570
-159,799
| -24% | -$1.1M | 0.01% | 1437 |
|
|
2014
Q1 | $5.46M | Buy |
677,369
+121,339
| +22% | +$945K | 0.02% | 1074 |
|
|
2013
Q4 | $3.79M | Buy |
556,030
+194,559
| +54% | +$1.05M | 0.01% | 1260 |
|
|
2013
Q3 | $6.65M | Buy |
361,471
+24,704
| +7% | +$480K | 0.02% | 963 |
|
|
2013
Q2 | $5.89M | Buy |
+336,767
| New | +$5.97M | 0.02% | 988 |
|
Other funds holding ARIA
Guggenheim Capital's ARIA Position: Q1 2017 in Review
Guggenheim Capital sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 253,807 shares — an estimated $3.16M sold.
Guggenheim Capital first reported a position in ARIA in Q2 2013 and held it in 15 quarters. The position peaked at $6.99M in Q2 2015. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.
- Guggenheim Capital reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
- Guggenheim Capital sold 253,807 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $3.16M.
- Guggenheim Capital first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
- Guggenheim Capital's Ariad Pharmaceuticals Inc position peaked at $6.99M in Q2 2015.
- 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.
Based on Guggenheim Capital's 13F filing for Q1 2017, filed 15 May 2017.